Ana sayfa
Piyasalar
Grafikler ve fikirler
Algo
Haberler
Store
Aracı kurumlar
İndir
Ekonomik Takvim
Alım-satım sinyalleri
Web Terminali
Arama yapmak için
/
tuşuna basın: @kullanıcı, $sembol, ...
Ara
Giriş yap
Hesap oluştur
Türkçe
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
NPCE
#2528
Neuropace, Inc. Common Stock
14.580
0
-0.95%
Sektör:
Baz:
Kar para birimi:
Günlük aralık
Yıllık aralık
Günlük değişim
-0.95%
Aylık değişim
-9.97%
6 aylık değişim
+37.81%
Yıllık değişim
+37.81%
Önceki kapanış
14.720
0
Open
14.580
0
Bid
Ask
Low
14.580
0
High
14.580
0
Hacim
30
Piyasalar
ABD hisse senetleri
Sağlık hizmetleri
NPCE
Open full chart
Financials
Overview
Rapor
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
29.85 M
32.56 M
32.8 M
33.08 M
33.31 M
—
Valuation ratios
Enterprise value
192.62 M
350.92 M
376.07 M
345.67 M
322.75 M
1.4 B
Price to earnings ratio
-7.04
-12.03
-14.99
-13.59
-13.93
-54.54
Price to sales ratio
2.54
4.08
4.3
3.82
3.41
15.61
Price to cash flow ratio
-11.78
-18.16
-20.53
-21.14
-19.56
-79.39
Price to book ratio
3.5
40.67
7.09
5.6
4.64
58.01
Enterprise value to EBITDA ratio
-8.52
-16.52
-19.93
-17.76
-18.14
-72.34
Profitability ratios
Return on assets %
0.06
0.06
0.06
0.08
0.03
0.23
Return on equity %
0.56
0.66
0.27
0.45
0.19
1.56
Return on invested capital %
60.48
—
67.6
88.98
34.72
—
Gross margin %
73.22
75.41
76.99
77.09
77.39
306.88
Operating margin %
20.15
17.02
22.85
29.01
9.51
78.39
EBITDA margin %
-19.45
-17
-22.42
-28.35
-8.88
-76.65
Net margin %
25.89
24.46
29.25
36.78
12.78
103.27
Liquidity ratios
Quick ratio
4.77
4.48
5.7
4.51
3.94
18.64
Current ratio
5.59
5.37
6.63
5.47
4.86
22.33
Inventory turnover
0.48
0.41
0.38
0.36
0.36
1.52
Asset turnover
0.22
0.22
0.22
0.22
0.26
0.92
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
0.62
0.63
0.54
0.55
0.55
2.27
Long term debt to total equity ratio
6.03
7.43
2.46
3.02
3.17
16.08
Per share metrics
Operating cash flow per share
0.06
0.16
0.24
0.06
0.06
0.52
EBIT per share
-0.14
-0.13
-0.16
-0.21
-0.08
-0.58
EBITDA per share
-0.14
-0.13
-0.16
-0.2
-0.07
-0.56
Total debt per share
—
—
—
—
—
—
Cash per share
1.93
1.81
2.11
1.89
1.81
7.62
Net current asset value per share
2.8
2.79
3.1
2.85
2.88
11.62
Tangible book value per share
0.33
0.28
0.77
0.59
0.56
2.2
Working capital per share
2.3
2.27
2.63
2.33
2.29
9.52
Book value per share
0.33
0.28
0.77
0.59
0.56
2.2
Haberler
LivaNova (LIVN) Tops Q4 Earnings and Revenue Estimates
Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
NeuroPace, Inc. (NPCE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Pacific Biosciences of California (PACB) Reports Q4 Loss, Beats Revenue Estimates
NeuroPace stock price target raised to $20 from $19 at Leerink Partners
NeuroPace stock price target raised to $19 from $18 at H.C. Wainwright
NeuroPace, Inc. (NPCE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
UBS, güçlü 4. çeyrek gelirinin ardından NeuroPace hissesi için Al tavsiyesini yineledi
NeuroPace stock rises as UBS reiterates Buy rating after strong Q4 revenue
NeuroPace 2025 için %25 gelir artışı bildirdi, istikrarlı büyüme öngörüyor
NeuroPace reports 25% revenue growth for 2025, projects steady growth
NeuroPace, epilepsi tedavisi için RNS Sistemi’nin genişletilmesi için FDA onayı istiyor